Table 1 Disease activity before and after the patients with juvenile idiopathic arthritis using methotrexate, who received the measles, mumps and rubella vaccination (n = 49)
Patients using methotrexate (n = 49)Before MMR*After MMR*p Value
Disease activity parameters
    Active joints1 (0 to 24)1 (0 to 14)0.016
    Limited joints1 (0 to 12)1 (0 to 3)0.198
    PGA0.7 (0.0 to 2.7)0.3 (0.0 to 1.8)0.004
    ESR12 (2 to 32)10 (2 to 33)0.016
Flares
    Per patient0 (0 to 3)0 (0 to 2)0.186
    Patients with ⩾1 flares, n (%)13 (26.5)21 (42.9)0.115
Medication
    Methotrexate dose/person, mg/m211 (7 to 25)11 (0 to 22)0.666
    Oral steroid dose per person, mg/kg0.0 (0.0 to 0.2)0.0 (0.0 to 0.2)0.333
    Patients on NSAIDs, n (%)45 (91.8)44 (89.8)1.000
    Patients on intra-articular steroids, n (%)9 (18.4)1 (2.0)0.008
    Patients on other DMARDs, n (%)6 (12.2)6 (12.2)1.000
    Patients on anti-TNFα therapy, n (%)1 (2.0)1 (2.0)1.000

  • DMARDs, disease-modifying anti-rheumatic drugs; MMR, measles, mumps and rubella; NSAIDs, non-steroidal anti-inflammatory drugs; TNF, tumour necrosis factor.

  • *Values are calculated for the period of 6 months before and after the MMR vaccination.

  • Data are median and range unless otherwise indicated; median and range are given if data are skewed.